MAGRIT: The largest-ever phase iii lung cancer trial aims to establish a novel tumor-specific approach to therapy

Clinical Lung Cancer

Volumn 10, Issue 5, 2009, Pages 371-374

  Tyagi, Preeta ^a   Mirakhur, Beloo ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Antigen specific cancer immunotherapeutics; Biomarkers; Cytolytic T cells; MAGE A3; Relapse

Indexed keywords

MELANOMA ANTIGEN 3;

ANTIGEN SPECIFICITY; CANCER IMMUNOTHERAPY; CANCER RELAPSE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SHORT SURVEY;

EID: 77249089345     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2009.n.052     Document Type: Article

References (30)

1. Garcia M, Jemal A, Ward EM, et al. Global Cancer Facts & Figures 2007. Atlanta, GA: American Cancer Society; 2007.
2. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008; 359:1367-1380
3. Wilking N, Jonsson BA. Pan-European comparison regarding patient access to cancer drugs. Karolinska Institute in collaboration with Stockholm School of Economics, Stockholm, Sweden, 2005.
4. Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008; 83:584-594
5. National Collaborating Centre for Acute Care. Diagnosis and Treatment of Lung Cancer. London: National Collaborating Centre for Acute Care; 2005.
6. Ramalingam S, Belani C. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist 2008; 13(Suppl 1):5-13.
7. Katzel JA, Fanucchi MP, Li Z. Recent advances of novel targeted therapy in non-small cell lung cancer. J Hematol Oncol 2009; 2:2.
8. Nauts HC. Bacteria and cancer-antagonisms and benefits. Cancer Surv 1989; 8:713-723
9. McCann J. Can skin cancers be minimized or prevented in organ transplant patients? J Natl Cancer Inst 1999; 91:911-913
10. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14:7-17.
11. Raez LE, Fein S, Podack ER. Lung cancer immunotherapy. Clin Med Res 2005; 3:221-228
12. Abu-Shakra M, Buskila D, Ehrenfeld M, et al. Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies. Ann Rheum Dis 2001; 60:433-441
13. Novellino L, Castelli C, Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 2005; 54:187-207.
14. Pardoll D. Does the immune system see tumors as foreign or self? Annu Rev Immunol 2003; 21:807-839
15. Hirschowitz EA, Hiestand DM, Yannelli JR. Vaccines for lung cancer. J Thorac Oncol 2006; 1:93-104.
16. Mitchell MS. Cancer vaccines, a critical review-Part I. Curr Opin Investig Drugs 2002; 3:140-149
17. Miyagawa N, Kono K, Mimura K, et al. A newly identified MAGE-3-derived, HLAA24 restricted peptide is naturally processed and presented as a CTL epitope on MAGE-3-expressing gastrointestinal cancer cells. Oncology 2006; 70:54-62.
18. Schultz ES, Lethe B, Cambiaso CL, et al. A MAGE-A3 peptide presented by HLADP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes. Cancer Res 2000; 60:6272-6275
19. Tatsumi T, Kierstead LS, Ranieri E, et al. MAGE-6 encodes HLA-DRbeta1*0401presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma. Clin Cancer Res 2003; 9:947-954
20. Zhou M, Peng JR, Zhang HG, et al. Identification of two naturally presented MAGE antigenic peptides from a patient with hepatocellular carcinoma by mass spectrometry. Immunol Lett 2005; 99:113-121 (Pubitemid 40718942)
21. Vansteenkiste J, Zielinski M, Linder A, et al. Final results of a multi-center, doubleblind, randomized, placebo controlled Phase II study to assess the efficacy of MAGEA3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). J Clin Oncol 2007; 25(suppl):398s (Abstract 7554).
22. Van den Eynde BJ, van der Bruggen P. T cell defined tumor antigens. Curr Opin Immunol 1997; 9:684-693
23. De Plaen E, Arden K, Traversari C, et al. Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 1994; 40:360-369
24. Boel P, Wildmann C, Sensi ML, et al. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 1995; 2:167-175
25. Schnurr M, Chen Q, Shin A, et al. Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. Blood 2005; 105:2465-2472
26. Brichard VG, Lejeune D. GSKs antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development. Vaccine 2007; 25(suppl 2):B61-71.
27. Marchand M, van Baren N, Weynants P, et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE3 and presented by HLA-A1. Int J Cancer 1999; 80:219-230
28. Hoos A, Parmiani G, Hege K, et al. A clinical development paradigm for cancer vaccines and related biologics. J Immunother 2007; 30:1-15.
29. Vansteenkiste JF, Zielinski M, Dahabreh IJ, et al. Association of gene expression signature and clinical efficacy of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) as adjuvant therapy in resected stage IB/II non-small cell lung cancer (NSCLC). J Clin Oncol 2008; 26(suppl):397s (Abstract 7501).
30. National Cancer Institute. Non-small cell lung cancer treatment (PDQ): general information. Available at: http://www.cancer.gov/cancertopics/pdq/ treatment/non-smallcelllung/HealthProfessional/page2. Last modified: August 1, 2008. Last accessed: November 20, 2008.